» Articles » PMID: 36016240

Time-Varying Effect of Hybrid Immunity on the Risk of Breakthrough Infection After Booster Dose of MRNA COVID-19 Vaccine: The MOSAICO Study

Overview
Date 2022 Aug 26
PMID 36016240
Authors
Affiliations
Soon will be listed here.
Abstract

This longitudinal observational study investigated the risk of breakthrough SARS-CoV-2 infection up to 6 months after a booster dose of an mRNA COVID-19 vaccine in infection-naïve vs. previously infected healthcare workers (HCWs), and whether this difference varied over time. A Cox proportional hazard regression model with Aalen's additive analysis was fitted to examine the association between the risk of infections and predictor variables. Overall, we observed an incidence rate of 2.5 cases per 1000 person-days (95% confidence interval [CI] 2.0-3.0), which dropped at 0.8 per 1000 person-days (95% CI 0.3-2.0) in recipients with prior SARS-CoV-2 infection. The fitted analysis indicated an adjusted hazard ratio of 0.32 (95% CI 0.13-0.80; -value = 0.01) for those with hybrid immunity with a slope that became steeply negative roughly starting from day 90. No difference was seen according to participants' smoking habits. Characteristics of infected HCWs were also described. Our study quantifies the time-varying effects of vaccine-induced and hybrid immunity after the booster dose (during the Omicron variant predominance in Italy) and observed that the protection waned more rapidly in infection-naïve recipients starting from the third month. The results add important evidence that can be used to inform COVID-19 vaccination strategies.

Citing Articles

COVID-19 Vaccination and Public Health: Addressing Global, Regional, and Within-Country Inequalities.

Santangelo O, Provenzano S, Di Martino G, Ferrara P Vaccines (Basel). 2024; 12(8).

PMID: 39204011 PMC: 11360777. DOI: 10.3390/vaccines12080885.


Dynamics of Anti-SARS-CoV-2 IgA and IgG Responses and Their Protective Effect against Fatal Disease after Booster COVID-19 Vaccination.

Speletas M, Voulgaridi I, Bogogiannidou Z, Sarrou S, Kyritsi M, Theodoridou A Vaccines (Basel). 2024; 12(1).

PMID: 38276671 PMC: 10819547. DOI: 10.3390/vaccines12010012.


Humoral Response after SARS-CoV-2 Vaccination in Prostate Cancer Patients.

Blaszczuk A, Sikora D, Kis J, Stepien E, Drop B, Polz-Dacewicz M Vaccines (Basel). 2023; 11(4).

PMID: 37112682 PMC: 10144447. DOI: 10.3390/vaccines11040770.


Importance, Applications and Features of Assays Measuring SARS-CoV-2 Neutralizing Antibodies.

Gattinger P, Ohradanova-Repic A, Valenta R Int J Mol Sci. 2023; 24(6).

PMID: 36982424 PMC: 10048970. DOI: 10.3390/ijms24065352.


Risk of Repeated Adverse Effects following Booster Dose of mRNA COVID-19 Vaccine: Results from the MOSAICO Study.

Ferrara P, Ponticelli D, Losa L, Romeo C, Magliuolo R, Vitale A Vaccines (Basel). 2023; 11(2).

PMID: 36851125 PMC: 9959434. DOI: 10.3390/vaccines11020247.


References
1.
DAlessandro V, Balasco N, Ferrara P, Vitagliano L . The temporal correlation between positive testing and death in Italy: from the first phase to the later evolution of the COVID-19 pandemic. Acta Biomed. 2022; 92(6):e2021395. PMC: 8823554. DOI: 10.23750/abm.v92i6.12030. View

2.
Sidik S . COVID vaccine plus infection can lead to months of immunity. Nature. 2022; . DOI: 10.1038/d41586-022-00961-3. View

3.
Ferrara P, Albano L . Azithromycin Has Been Flying Off the Shelves: The Italian Lesson Learnt from Improper Use of Antibiotics against COVID-19. Medicina (Kaunas). 2022; 58(3). PMC: 8955327. DOI: 10.3390/medicina58030363. View

4.
Gazit S, Shlezinger R, Perez G, Lotan R, Peretz A, Ben-Tov A . Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Naturally Acquired Immunity versus Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: A Retrospective Cohort Study. Clin Infect Dis. 2022; 75(1):e545-e551. PMC: 9047157. DOI: 10.1093/cid/ciac262. View

5.
Ponticelli D, Antonazzo I, Caci G, Vitale A, Della Ragione G, Romano M . Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine after 6 months. J Travel Med. 2021; 28(8). DOI: 10.1093/jtm/taab173. View